Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Biochemistry

Volumn 45, Issue 36, 2006, Pages 10963-10972

  Liu, Dongxiang ^a   Xu, Yechun ^a   Feng, Yu ^a   Liu, Hong ^a   Shen, Xu ^a,b   Chen, Kaixian ^a   Ma, Jianpeng ^c,d   Jiang, Hualiang ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMIC FORCE MICROSCOPY; BIOASSAY; DISEASES; MOLECULAR DYNAMICS; NEUROLOGY;

Β-AMYLOID PEPTIDE; ALZHEIMER'S DISEASE; FIBRILLATION; MOLECULAR DYNAMICS SIMULATIONS;

ENZYME INHIBITION;

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PROTEIN INHIBITOR; PROTEIN INHIBITOR DC AB1; THIOFLAVINE; UNCLASSIFIED DRUG;

ALPHA HELIX; ALZHEIMER DISEASE; ARTICLE; ATOMIC FORCE MICROSCOPY; BETA SHEET; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG STRUCTURE; FIBER; FLUORESCENCE; HYDROGEN BOND; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN CONTENT; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; RANDOM COIL; SENILE PLAQUE;

AMYLOID; AMYLOID BETA-PROTEIN; BENZHYDRYL COMPOUNDS; BINDING SITES; BIOCHEMISTRY; CIRCULAR DICHROISM; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE; MICROSCOPY, ATOMIC FORCE; MODELS, MOLECULAR; MORPHOLINES; PROTEIN CONFORMATION; THIAZOLES;

EID: 33748504563     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi060955f     Document Type: Article

References (70)

1. Geula, C., Wu, C. K., Saroff, D., Lorenzo, A., Yuan, M., and Yankner, B. A. (1998) Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity, Nat. Med. 4, 827-831.
2. Glenner, G. G., and Wong, C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem. Biophys. Res. Commun. 120, 885-890.
3. Selkoe, D. J. (1994) Alzheimer's disease: a central role for amyloid, J. Neuropathol. Exp. Neurol. 53, 438-447.
4. Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., and Ihara, Y. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43), Neuron 13, 45-53.
5. Suzuki, N., Cheung, T. T., Cai, X. D., Odaka, A., Otvos, L. J., Eckman, C., Golde, T. E., and Younkin, S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants, Science 264, 1336-1340.
6. Dahlgren, K. N., Manelli, A. M., Stine, W. B. J., Baker, L. K., Krafft, G. A., and LaDu, M. J. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability, J. Biol. Chem. 277, 32046-32053.
7. Selkoe, D. J. (1999) Translating cell biology into therapeutic advances in Alzheimer's disease, Nature 399, A23-A31.
8. Kagan, B. L., Hirakura, Y., Azimov, R., Azimova, R., and Lin, M. C. (2002) The channel hypothesis of Alzheimer's disease: current status, Peptides 23, 1311-1315.
9. Monji, A., Utsumi, H., Ueda, T., Imoto, T., Yoshida, I., Hashioka, S., Tashiro, K., and Tashiro, N. (2001) The relationship between the aggregational state of the amyloid-beta peptides and free radical generation by the peptides, J. Neurochem. 77, 1425-1432.
10. Sultana, R., Newman, S., Mohmmad-Abdul, H., Keller, J. N., and Butterfield, D. A. (2004) Protective effect of the xanthate, D609, on Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress in primary neuronal cells, Free Radical Res. 38, 449-458.
11. Tabner, B. J., El-Agnaf, O. M., Turnbull, S., German, M. J., Paleologou, K. E., Hayashi, Y., Cooper, L. J., Fullwood, N. J., and Allsop, D. (2005) Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia, J. Biol. Chem. 280, 35789-35792.
12. Holtzman, D. M. (2004) In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology, J. Mol. Neurosci. 23, 247-254.
13. Lauderback, C. M., Kanski, J., Hackett, J. M., Maeda, N., Kindy, M. S., and Butterfield, D. A. (2002) Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner, Brain Res. 924, 90-97.
14. Sadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A., Li, Y., Schmidt, S. D., Mathews, P. M., Fryer, J. D., Holtzman, D. M., Sigurdsson, E. M., and Wisniewski, T. (2004) A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am. J. Pathol. 165, 937-948.
15. Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., Trinchese, F., Liu, S., Gunn-Moore, F., Lue, L. F., Walker, D. G., Kuppusamy, P., Zewier, Z. L., Arancio, O., Stern, D., Yan, S. S., and Wu, H. (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease, Science 304, 448-452.
16. Oppermann, U. C., Salim, S., Tjernberg, L. O., Terenius, L., and Jornvall, H. (1999) Binding of amyloid beta-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease, FEBS Lett. 451, 238-242.
17. Klein, W. L., Krafft, G. A., and Finch, C. E. (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219-224.
18. Lansbury, P. T., Jr. (1997) Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease, Curr. Opin. Chem. Biol. 1, 260-267.
19. Danielsson, J., Jarvet, J., Damberg, P., and Graslund, A. (2005) The Alzheimer beta-peptide shows temperature-dependent transitions between left-handed 3-helix, beta-strand and random coil secondary structures, FEBS J. 272, 3938-3949.
20. Zhang, S., Iwata, K., Lachenmann, M. J., Peng, J. W., Li, S., Stimson, E. R., Lu, Y., Felix, A. M., Maggio, J. E., and Lee, J. P. (2000) The Alzheimer's peptide a beta adopts a collapsed coil structure in water, J. Struct. Biol. 130, 130-141.
21. Crescenzi, O., Tomaselli, S., Guerrini, R., Salvadori, S., D'Ursi, A. M., Temussi, P. A., and Picone, D. (2002) Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain, Eur. J. Biochem. 269, 5642-5648.
22. Fezoui, Y., and Teplow, D. B. (2002) Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization, J. Biol. Chem. 277, 36948-36954.
23. Sticht, H., Bayer, P., Willbold, D., Dames, S., Hilbich, C, Beyreuther, K., Frank, R. W., and Rosch, P. (1995) Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease, Eur. J. Biochem. 233, 293-298.
24. Vieira, E. P., Hermel, H., and Mohwald, H. (2003) Change and stabilization of the amyloid-beta(1-40) secondary structure by fluorocompounds, Biochim. Biophys. Acta 1645, 6-14.
25. Barrow, C. J., Yasuda, A., Kenny, P. T., and Zagorski, M. G. (1992) Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra, J. Mol. Biol. 225, 1075-1093.
26. Coles, M., Bicknell, W., Watson, A. A., Fairlie, D. P., and Craik, D. J. (1998) Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 37, 11064-11077.
27. Stine, W. B. J., Dahlgren, K. N., Krafft, G. A., and LaDu, M. J. (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis, J. Biol. Chem. 278, 11612-11622.
28. Kirschner, D. A., Abraham, C., and Selkoe, D. J. (1986) X-ray diffraction from intraneuronal paired helical filaments and extra-neuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation, Proc. Natl. Acad Sci. U.S.A. 83, 2776.
29. Ippel, J. H., Olofsson, A., Schleucher, J., Lundgren, E., and Wijmenga, S. S. (2002) Probing solvent accessibility of amyloid fibrils by solution NMR spectroscopy, Proc. Natl. Acad. Sci. U.S.A. 99, 8648-8653.
30. Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D., and Riek, R. (2005) 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. U.S.A. 102, 17342-17347.
31. Kirkitadze, M. D., Condron, M. M., and Teplow, D. B. (2001) Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis, J. Mol. Biol. 312, 1103-1119.
32. Mandal, P. K., and Pettegrew, J. W. (2004) Alzheimer's disease: soluble oligomeric Abeta(1-40) peptide in membrane mimic environment from solution NMR and circular dichroism studies, Neurochem. Res. 29, 2267-2272.
33. Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., and Teplow, D. B. (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates, J. Biol. Chem. 274, 25945-25952.
34. Howlett, D. R., George, A. R., Owen, D. E., Ward, R. V., and Markwell, R. E. (1999) Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation, Biochem. J. 343, 419-423.
35. Howlett, D. R., Perry, A. E., Godfrey, F., Swatton, J. E., Jennings, K. H., Spitzfaden, C., Wadsworth, H., Wood, S. J., and Markwell, R. E. (1999) Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans, Biochem. J. 340, 283-289.
36. Abe, K., Kato, M., and Saito, H. (1997) Congo red reverses amyloid beta protein-induced cellular stress in astrocytes, Neurosci. Res. 29, 129-134.
37. Lee, V. M. (2002) Amyloid binding ligands as Alzheimer's disease therapies, Neurobiol. Aging 23, 1039-1042.
38. Zhuang, Z. P., Kung, M. P., Hou, C., Skovronsky, D. M., Gur, T. L., Plössl, K., Trojanowski, J. Q., Lee, V. M., and Kung, H. F. (2001) Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates, J. Med. Chem. 44, 1905-1914.
39. Kim, H., Park, B. S., Lee, K. G., Choi, C. Y., Jang, S. S., Kim, Y. H., and Lee, S. E. (2005) Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid, J. Agric. Food Chem. 53, 8537-8341.
40. Gordon, D. J., Sciarretta, K. L., and Meredith, S. C. (2001) Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues, Biochemistry 40, 8237-8245.
41. Kisilevsky, R., Szarek, W., and Weaver, D. (1999) Method for treating amyloidosis, U.S. Patent 5,972,328.
42. Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y., Huang, X., Goldstein, L. E., Moir, R. D., Lim, J. T., Beyreuther, K., Zheng, H., Tanzi, R. E., Masters, C. L., and Bush, A. I. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice, Neuron 30, 665-676.
43. Dominguez, D. L, and De Strooper, B. (2002) Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease, Trends Pharmacol. Sci. 23, 324-330.
44. Helmuth, L. (2000) An antibiotic to treat Alzheimer's? Science 290, 1273-1274.
45. Tabira, T. (2001) Clioquinol's return: cautions from Japan. Science 292, 2251-2252.
46. Xu, Y., Shen, J., Luo, X., Zhu, W., Chen, K., Ma, J., and Jiang, H. (2005) Conformational transition of amyloid beta-peptide, Proc. Natl. Acad. Sci. U.S.A. 102, 5403-5407.
47. Ewing, T. J. A., and Kuntz, I. D. (1997) Critical evaluation of search algorithms for automated molecular docking and database screening, J. Comput. Chem. 18, 1175-11789.
48. Kuntz, I. D. (1992) Structure-based strategies for drug design and discovery, Science 257, 1078-1082.
49. Clark, R. D., Strizhev, A., Leonard, J. M., Blake, J. F., and Matthew, J. B. (2002) Consensus scoring for ligand/protein interactions, J. Mol. Graphics Modell. 20, 281-295.
50. Lee, K. H., Shin, B. H., Shin, K. J., Kim, D. J., and Yu, J. (2005) A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid(1-42), Biochem. Biophys. Res. Commun. 328, 816-823.
51. Bohm, G., Murh, R., and Jaenicke, R. (1992) Quantitative analysis of protein far UV circular dichroism spectra by neural networks, Protein Eng. 5, 191-195.
52. LeVine, H., III. (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution, Protein Sci. 2, 404-410.
53. Lomakin, A., Teplow, D. B., Kirschner, D. A., and Benedek, G. B. (1997) Kinetic theory of fibrillogenesis of amyloid beta-protein, Proc. Natl. Acad. Sci. U.S.A. 94, 7942-7947.
54. LeVine, H., III. (1995) Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution, Neurobiol. Aging 16, 755-764.
55. Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B., Kagan, B., Ghiso, J., and Lal, R. (2005) Amyloid ion channels: a common structural link for protein-misfolding disease, Proc. Natl. Acad. Sci. U.S.A. 102, 10427-10432.
56. Clippingdale, A. B., Macris, M., Wade, J. D., and Barrow, C. J. (1999) Synthesis and secondary structural studies of penta(acetyl-Hmb)A beta(1-40), J. Pept. Res. 53, 665-672.
57. Tjernberg, L. O., Naslund, J., Lindqvist, F., Johansson, J., Karlstrom, A. R., Thyberg, J., Terenius, L., and Nordstedt, C. (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand, J. Biol. Chem. 12, 15.
58. Fulop, L., Zarandi, M., Datki, Z., Soos, K., and Penke, B. (2004) Beta-amyloid-derived pentapeptide RIIGLa inhibits Abeta(1-42) aggregation and toxicity, Biochem. Biophys. Res. Commun. 324, 64-69.
59. Petty, S. A., and Decatur, S. M. (2005) Intersheet rearrangement of polypeptides during nucleation of {beta}-sheet aggregates, Proc. Natl. Acad. Sci. U.S.A. 1753, 108-120.
60. Stromer, T., and Serpell, L. C. (2005) Structure and morphology of the Alzheimer's amyloid fibril, Microsc. Res. Tech. 67, 210-217.
61. Modler, A. J., Gast, K., Lutsch, G., and Damaschun, G. (2003) Assembly of amyloid protofibrils via critical oligomers-a novel pathway of amyloid formation, J. Mol Biol. 325, 135-148.
62. Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R. S., Harlan, J., Barlow, E., Ebert, U., and Hillen, H. (2005) Globular amyloid beta-peptide oligomer: a homogeneous and stable neuropathological protein in Alzheimer's disease, J. Neurochem. 95, 834-847.
63. Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., and Teplow, D. B. (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate, J. Biol. Chem. 272, 22364-22372.
64. LeVine, H., III. (2004) Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal. Biochem. 335, 81-90.
65. Bitan, G., Lomakin, A., and Teplow, D. B. (2001) Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins, J. Biol. Chem. 276, 35176-35184.
66. Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S., Benedek, G. B., and Teplow, D. B. (2003) Amyloid beta -protein (Abeta) assembly. Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. U.S.A. 100, 330-335.
67. Bitan, G., and Teplow, D. B. (2004) Rapid photochemical crosslinking-a new tool for studies of metastable, amyloidogenic protein assemblies, Acc. Chem. Res. 37, 357-364.
68. Podlisny, M. B., Ostaszewski, B. L., Squazzo, S. L., Koo, E. H., Rydell, R. E., Teplow, D. B., and Selkoe, D. J. (1995) Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture, J. Biol. Chem. 270, 9564-9670.
69. Jorgensen, W. L. (2004) The many roles of computation in drug discovery, Science 303, 1813-1818.
70. Congreve, M., Murray, C. W., and Blundell, T. L. (2005) Structural biology and drug discovery, Drug Discovery Today 10, 895-907.